<DOC>
	<DOCNO>NCT00002517</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know regimen combination chemotherapy effective acute myeloid leukemia myelodysplastic syndrome . PURPOSE : Randomized phase III trial compare effectiveness different combination chemotherapy regimens treat child newly diagnose acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Newly Diagnosed Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy idarubicin v mitoxantrone induction first intensification term achieve maintain complete remission child acute myeloid leukemia myelodysplastic syndrome . OUTLINE : This randomize , multicenter study . Patients stratify accord center disease type ( de novo acute myeloid leukemia ( AML ) v AML secondary myelodysplastic syndrome ( MDS ) v MDS ) . - Induction : Patients randomize 1 2 treatment arm . - Arm I : Patients receive cytarabine ( ARA-C ) IV continuously day 1 2 IV 30 minute every 12 hour day 3-8 , mitoxantrone IV day 3-5 , etoposide ( VP-16 ) IV 1 hour day 6-8 , ARA-C intrathecally ( IT ) day 1 8 . - Arm II : Patients receive ARA-C VP-16 arm I idarubicin IV day 3-5 . Patients arm CNS disease presentation receive ARA-C IT every 3 day CSF clear weekly first intensification . After induction , patient arm proceed first intensification , regardless response . - First intensification : When blood count recover within 40 day initiate induction , patient randomize 1 2 treatment arm . - Arm III : Patients receive high-dose ARA-C IV 3 hour every 12 hour day 1-3 ( allogeneic bone marrow transplantation ( BMT ) plan ) day 1-4 ( allogeneic BMT plan ) mitoxantrone IV day 7-9 . - Arm IV : Patients receive high-dose ARA-C arm III idarubicin IV day 7-9 . - Patients achieve complete remission ( CR ) first intensification HLA-identical , chronic myelomonocytic leukemia-nonreactive , sibling donor undergo allogeneic BMT . Patients achieve CR intensification suitable donor receive intensive chemotherapy define . All patient chloroma presentation undergo local radiotherapy begin final intensification . - Second intensification : When blood count recover , patient receive daunorubicin IV continuously , ARA-C IV continuously , VP-16 IV continuously , oral thioguanine , oral dexamethasone day 1-4 11-14 ARA-C IT day 1 , 4 , 11 , 14 . - Third intensification : When blood count recover , patient receive high-dose ARA-C IV 3 hour every 12 hour day 1-3 VP-16 IV 1 hour day 2-5 . When blood count recover , autologous bone marrow harvest event subsequent relapse . - Maintenance : When blood count recover , patient receive oral thioguanine daily ARA-C subcutaneously 4 day month 1 year . PROJECTED ACCRUAL : A total 310 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia ( AML ) base cytological , cytochemical , immunological criterion FAB classification Must meet 1 follow criterion : More 30 % blast marrow ( calculation base total number nucleate cell except lymphocyte plasmocytes ) Presence granulocytic sarcoma ( chloroma ) Disease must associate least 1 follow : More 3 % myeloperoxidase Sudan blackpositive blast More 3 % platelet peroxidasepositive blast More 20 % esterasepositive blast Immunological marker compatible myeloid differentiation , include 1 follow criterion : Blasts positive myeloidassociated antigen negative B Tlymphocyte antigens Blasts positive least 2 myeloid antigen ( except CD3 CD8 ) A cytogenetic abnormality associate AML OR Newly diagnose myelodysplastic syndrome ( MDS ) base cytological cytochemical criterion FAB classification Eligible subtypes : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia No promyelocytic leukemia ( M3 M3v ) treat tretinoin ( protocol EORTC06915 ) No AML secondary hematologic malignant disease MDS Registration must occur within 48 hour diagnosis PATIENT CHARACTERISTICS : Age : Under 15 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics No uncontrolled bleed disorder Hepatic : Not specify Renal : No renal failure Cardiovascular : No congenital heart disease Other : No encephalopathy No genetic disorder No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior antileukemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>